Literature DB >> 11092714

HIV-associated tuberculosis in the era of highly active antiretroviral therapy. The Adult/Adolescent Spectrum of HIV Disease Group.

J L Jones1, D L Hanson, M S Dworkin, K M DeCock.   

Abstract

OBJECTIVE: To determine the effect of highly active antiretroviral therapy (HAART) on the risk of tuberculosis (TB) among persons infected with the human immunodeficiency virus (HIV), and to examine trends in TB.
METHODS: For the risk factor analysis, we examined data from the Adult/Adolescent Spectrum of HIV Disease (ASD) project from January 1996 through June 1998. ASD is an observational cohort study conducted in over 100 clinics and hospitals in 11 US cities. Poisson regression was used to model the incidence of TB while controlling for HIV-exposure mode, race, country of birth, CD4 count, TB preventive therapy, and half-year of diagnosis. We also examined trends in TB incidence January 1992 to June 1998.
RESULTS: During the risk factor analysis period, 80 cases of TB occurred in 16,032 person-years (5.0 cases/1000 person-years). In multivariate analysis, the risk of TB was much lower among persons prescribed HAART (RR = 0.2, 95%CI 0.1-0.5, P < 0.001), and also lower among persons prescribed other antiretroviral therapy (RR = 0.6, 95% CI 0.4-1.0, P = 0.05), than the risk in persons not prescribed antiretroviral therapy. In addition, TB rates declined from January 1992 to June 1998 (P < 0.001).
CONCLUSION: Widespread use of HAART reduced the risk for TB and may help bring about further declines in TB among persons infected with HIV.

Entities:  

Mesh:

Year:  2000        PMID: 11092714

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  43 in total

1.  Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies.

Authors:  Annelies Van Rie; Daniel Westreich; Ian Sanne
Journal:  J Acquir Immune Defic Syndr       Date:  2011-04       Impact factor: 3.731

2.  Antiretroviral therapy for tuberculosis control in nine African countries.

Authors:  Brian G Williams; Reuben Granich; Kevin M De Cock; Philippe Glaziou; Abhishek Sharma; Christopher Dye
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-25       Impact factor: 11.205

3.  The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) study.

Authors:  Betina Durovni; Solange C Cavalcante; Valeria Saraceni; Vitoria Vellozo; Giselle Israel; Bonnie S King; Silvia Cohn; Anne Efron; Antonio G Pacheco; Lawrence H Moulton; Richard E Chaisson; Jonathan E Golub
Journal:  AIDS       Date:  2010-11       Impact factor: 4.177

4.  Tuberculosis risk before and after highly active antiretroviral therapy initiation: does HAART increase the short-term TB risk in a low incidence TB setting?

Authors:  April C Pettit; Cathy A Jenkins; Samuel E Stinnette; Peter F Rebeiro; Robert B Blackwell; Stephen P Raffanti; Bryan E Shepherd; Timothy R Sterling
Journal:  J Acquir Immune Defic Syndr       Date:  2011-08-01       Impact factor: 3.731

5.  Implementation and Operational Research: Declining Tuberculosis Incidence Among People Receiving HIV Care and Treatment Services in East Africa, 2007-2012.

Authors:  Suzue Saito; Philani Mpofu; E Jane Carter; Lameck Diero; Kara K Wools-Kaloustian; Constantin T Yiannoutsos; Musick S Beverly; Simon Tsiouris; Geoffrey R Somi; John Ssali; Denis Nash; Batya Elul
Journal:  J Acquir Immune Defic Syndr       Date:  2016-04-01       Impact factor: 3.731

Review 6.  Seventy Years of Tuberculosis Prevention: Efficacy, Effectiveness, Toxicity, Durability, and Duration.

Authors:  Nicole Salazar-Austin; David W Dowdy; Richard E Chaisson; Jonathan E Golub
Journal:  Am J Epidemiol       Date:  2019-12-31       Impact factor: 4.897

7.  The Impact of HIV Infection on TB Disparities Among US-Born Black and White Tuberculosis Patients in the United States.

Authors:  Suzanne M Marks; Dolly J Katz; Amy L Davidow; Melissa A Pagaoa; Larry D Teeter; Edward A Graviss
Journal:  J Public Health Manag Pract       Date:  2019-02-14

8.  Anti-retroviral therapy reduces incident tuberculosis in HIV-infected children.

Authors:  Andrew Edmonds; Jean Lusiama; Sonia Napravnik; Faustin Kitetele; Annelies Van Rie; Frieda Behets
Journal:  Int J Epidemiol       Date:  2009-05-15       Impact factor: 7.196

9.  The burden and characteristics of tuberculosis/human immunodeficiency virus (TB/HIV) in South Korea: a study from a population database and a survey.

Authors:  Chang-Hoon Lee; Ji-Young Hwang; Dae-Kyu Oh; Mee-Kyung Kee; Eunjung Oh; Jung-Wook An; Jinhyun Kim; Heonsook Do; Hee-Jin Kim; Sung Soon Kim; Hwahyun Kim; Jeong-Gu Nam
Journal:  BMC Infect Dis       Date:  2010-03-12       Impact factor: 3.090

Review 10.  Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings.

Authors:  Stephen D Lawn; Katharina Kranzer; Robin Wood
Journal:  Clin Chest Med       Date:  2009-12       Impact factor: 2.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.